Latest Breaking News On - சீனா நிலை உணவு - Page 1 : comparemela.com

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Eteläuomen läiEthics committee of henan provincial centerNational megaDrug administrationNational mega projects of chinaShangqiu city liangyuan district centerHenan provincial centerElsevier ltdTechnology planInstitute of biological productsChina national biotec groupChinese national medical products administrationNational medical products administrationDisease controlKey research projectMajor infectious diseases

What You Must Know About APAC Before Deploying Your Next Clinical Trial

What You Must Know About APAC Before Deploying Your Next Clinical Trial By Ed Miseta, Chief Editor, Clinical Leader Follow Me On Twitter @EdClinical Right now, no place in the world is a hotter spot to conduct clinical trials that the Asian-Pacific region (APAC). This popularity of the region is not new. In 2018 China was one of the hottest topics of conversation I heard at the DIA Annual Meeting. Shortly thereafter I wrote an article that featured the insights of three experts on that region. A year later the region was still attracting a lot of excitement when I produced this piece discussing how South Korea was a growing hot spot for trials. Today, the entire region remains an area of interest for clinical studies.

New zealandHong kongSouth koreaThe philippinesEd misetaMichaelw youngInternational council for harmonizationChinese centre for drug evaluationDrug administrationThermo fisherSyneos healthLabcorp drug developmentLife sciences consultingtheResearch development rd tax incentiveLife sciences consultingChief editor